.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Johnson and Johnson
Merck
Baxter
Dow
US Department of Justice
Boehringer Ingelheim
Accenture
Daiichi Sankyo
Covington

Generated: November 19, 2017

DrugPatentWatch Database Preview

SAXENDA Drug Profile

« Back to Dashboard

Which patents cover Saxenda, and what generic Saxenda alternatives are available?

Saxenda is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are fifteen patents protecting this drug.

This drug has two hundred and twelve patent family members in twenty-four countries and ten supplementary protection certificates in eight countries.

The generic ingredient in SAXENDA is liraglutide recombinant. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the liraglutide recombinant profile page.

Pharmacology for SAXENDA

Medical Subject Heading (MeSH) Categories for SAXENDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SAXENDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014► Subscribe► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SAXENDA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,384,016 Stabilized aqueous peptide solutions► Subscribe
8,357,120Injection device with torsion spring and rotatable display► Subscribe
9,616,180Automatic injection device with a top release mechanism► Subscribe
7,686,786Dial-down mechanism for wind-up pen► Subscribe
8,097,698Derivatives of GLP-1 analogs► Subscribe
7,226,990Extendin derivatives► Subscribe
8,096,978Automatic injection device with a top release mechanism► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SAXENDA

Country Document Number Estimated Expiration
Japan4643122► Subscribe
World Intellectual Property Organization (WIPO)9808871► Subscribe
Russian Federation2007114761► Subscribe
World Intellectual Property Organization (WIPO)2006045526► Subscribe
Japan5340603► Subscribe
Norway325273► Subscribe
Portugal1351732► Subscribe
Canada2468374► Subscribe
World Intellectual Property Organization (WIPO)9943707► Subscribe
Denmark1412384► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SAXENDA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0054France► SubscribePRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630
C034/2009Ireland► SubscribeSPC034/2009: 20101001, EXPIRES: 20220821
00698Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918
2014000114Germany► SubscribePRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918
2209800/01Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014
90067-4Sweden► SubscribePRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
C0085France► SubscribePRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918
C/GB09/058United Kingdom► SubscribePRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630
2009 00041Denmark► Subscribe
0944648/01Switzerland► SubscribePRODUCT NAME: LIRAGLUTID; REGISTRATION NO/DATE: SWISSMEDIC 59329 11.12.2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Federal Trade Commission
Chubb
Fuji
McKesson
US Army
Argus Health
Dow
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot